Clin Res Hepatol Gastroenterol 2021;45:101568.ArticlePubMed 119
The drug is a once-a-week injection that combines two hormones, GLP-1 and GIP, which work in combination to stimulate insulin secretion and reduce appetite
[8] [9] [10] [11] Although reduced GLP-1 secretion has previously been associated with attenuated incretin effect in patients with type 2 diabetes, further research indicates that GLP-1 secretion in patients with type 2 diabetes does not differ from healthy subjects
Innovent's trial data comes just weeks after Eli Lilly announced positive topline results from its phase 3 ACHIEVE-2 and ACHIEVE-5 trials of orforglipron, its oral GLP-1 receptor agonist for treating type 2 diabetes
In the SUSTAIN-6 trial, semaglutide was associated with a significant increased risk of diabetic retinopathy complications, including vitreous hemorrhage, blindness, or conditions requiring treatment with an intravitreal agent or photocoagulation (HR 1.76, 95% CI 1.112.78) [27]
In 2021, the sales of Lilly's long-acting GLP-1 receptor agonist product dulaglutide were US$6.472 billion, up 49% from the previous year